ALACHUA, Fla., December 17, 2024 – RTI Surgical ("the Company"), a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine, today unveils its new corporate identity as Evergen, signaling its strategic evolution into a premier Contract Development and Manufacturing Organization (CDMO) providing biosolutions in regenerative medicine.
The rebranding follows a transformative year marked by the successful acquisitions of Cook Biotech and Collagen Solutions, establishing Evergen as the industry's only CDMO offering a comprehensive portfolio of allograft and xenograft biomaterials at scale.
The new identity embodies Evergen's commitment to innovation, quality, and patient-centered solutions in regenerative medicine. This strategic repositioning reinforces the Company's dedication to setting new industry benchmarks through customized solutions for its customers across key high-growth therapeutic areas including cardiac, sports medicine, orthopedic surgery, neurosurgery, plastic and reconstructive surgery.
Olivier Visa, President and Chief Executive Officer, Evergen, said: “This rebranding marks a defining moment in our Company's evolution. Every decision we make begins with understanding patient needs and developing flexible, high-quality solutions that enable our customers to meet these needs effectively. As Evergen, we are positioned to lead a new era of regenerative medicine by becoming the trusted CDMO of choice for OEM partners.”
Kim Spooner, Chief People Officer, Evergen added: “Our new brand identity honors our rich heritage and unifies our employees as we become one team. As the newer businesses have integrated, it has been clear that there is a strong cultural affinity across our teams. I look forward to seeing how this further strengthens in the months and years ahead.”
Visit the Company's new website at: www.evergenbio.com